Determinants of Plasma Adiponectin Levels in Nondiabetic Subjects With Moderate to Severe Chronic Kidney Disease

Journal of Renal Nutrition

Volumn 19, Issue 3, 2009, Pages 197-203

  Ramos, Luis F ^a   Shintani, Ayumi ^a   Himmelfarb, Jonathan ^b   Ikizler, T Alp ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; LIPOPROTEIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; AGED; ARTICLE; BLOOD; BODY MASS; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; SEX DIFFERENCE;

ADIPONECTIN; ADIPOSE TISSUE; AGED; BODY MASS INDEX; C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TRIGLYCERIDES;

EID: 64849102025     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2009.01.028     Document Type: Article

References (39)

1. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
2. Tilg H., and Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6 (2006) 772-783
3. Koerner A., Kratzsch J., and Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19 (2005) 525-546
4. Arita Y., Kihara S., Ouchi N., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105 (2002) 2893-2898
5. Chen M.P., Tsai J.C., Chung F.M., et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25 (2005) 821-826
6. Cnop M., Havel P.J., Utzschneider K.M., et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46 (2003) 459-469
7. Kojima S., Funahashi T., Sakamoto T., et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89 (2003) 667
8. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atherosclerosis 6 Suppl (2005) 7-14
9. Nakamura Y., Shimada K., Fukuda D., et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 90 (2004) 528-533
10. Steffes M.W., Gross M.D., Lee D.H., Schreiner P.J., and Jacobs Jr. D.R. Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: the Coronary Artery Risk Development in Young Adults Study. Obesity (Silver Spring) 14 (2006) 319-326
11. Barazzoni R., Biolo G., Zanetti M., Bernardi A., and Guarnieri G. Inflammation and adipose tissue in uremia. J Ren Nutr 16 (2006) 204-207
12. Huang J.W., Yen C.J., Chiang H.W., Hung K.Y., Tsai T.J., and Wu K.D. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 43 (2004) 1047-1055
13. Ignacy W., Chudek J., Adamczak M., et al. Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease-a follow-up study. Nephron Clin Pract 101 (2005) c18-c24
14. Malyszko J., Wolczynski S., and Mysliwiec M. Adiponectin, leptin and thyroid hormones in patients with chronic renal failure and on renal replacement therapy: are they related?. Nephrol Dial Transplant 21 (2006) 145-152
15. Odamaki M., Furuya R., Kinumura Y., Ikegaya N., and Kumagai H. Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron Clin Pract 102 (2006) c8-c13
16. Shoji T., Shinohara K., Hatsuda S., et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metabolism 54 (2005) 330-334
17. Stenvinkel P., Marchlewska A., Pecoits-Filh R., et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65 (2004) 274-281
18. Zoccali C., Mallamaci F., Tripepi G., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141
19. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
20. Genuth S., Alberti K.G., Bennett P., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
21. Trirogoff M.L., Shintani A., Himmelfarb J., and Ikizler T.A. Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3-4 chronic kidney disease patients. Am J Clin Nutr 86 (2007) 1642-1648
22. Kanauchi M., Akai Y., and Hashimoto T. Validation of simple indices to assess insulin sensitivity and pancreatic beta-cell function in patients with renal dysfunction. Nephron 92 (2002) 713-715
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
24. Shoji T., Emoto M., and Nishizawa Y. HOMA index to assess insulin resistance in renal failure patients. Nephron 89 (2001) 348-349
25. Lukaski H.C., Johnson P.E., Bolonchuk W.W., and Lykken G.I. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr 41 (1985) 810-817
26. Ejerblad E., Fored C.M., Lindblad P., Fryzek J., McLaughlin J.K., and Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol 17 (2006) 1695-1702
27. Gelber R.P., Kurth T., Kausz A.T., et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 46 (2005) 871-880
28. Hsu C.Y., McCulloch C.E., Iribarren C., Darbinian J., and Alan S. Body mass index and risk for end-stage renal disease. Ann Intern Med 144 (2006) 21-28
29. Kramer H., Luke A., Bidani A., Cao G., Cooper R., and McGee D. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 46 (2005) 587-594
30. Evans M., Fryzek J.P., Elinder C.G., et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis 46 (2005) 863-870
31. Madero M., Sarnak M.J., Wang X., et al. Body mass index and mortality in CKD. Am J Kidney Dis 50 (2007) 404-411
32. Muntner P., He J., Astor B.C., Folsom A.R., and Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 16 (2005) 529-538
33. Nishizawa H., Shimomura I., Kishida K., et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51 (2002) 2734-2741
34. Guebre-Egziabher F., Bernhard J., Funahashi T., Hadj-Aissa A., and Fouque D. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 20 (2005) 129-134
35. Becker B., Kronenberg F., Kielstein J.T., et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the Mild and Moderate Kidney Disease Study. J Am Soc Nephrol 16 (2005) 1091-1098
36. Menon V., Li L., Wang X., et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17 (2006) 2599-2606
37. Zoccali C., Tripepi G., Cambareri F., et al. Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. J Ren Nutr 15 (2005) 125-130
38. Zoccali C., and Mallamaci F. Adiponectin and renal disease progression: another epidemiologic conundrum?. Kidney Int 71 (2007) 1195-1197
39. Kollerits B., Fliser D., Heid I.M., Ritz E., and Kronenberg F. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 71 (2007) 1279-1286